Translating diagnostic innovation and governed clinical AI into clinical impact.
Translyx Limited brings advanced diagnostics, authorised digital pathology AI, and Privexa-built protected AI workflows to New Zealand and Oceania — helping clinicians, laboratories, healthcare providers, and research teams adopt innovation with privacy, governance, and clinical confidence.
Privacy · Governance · Clinical Impact
Digital Pathology AI
Privexa Software
Governed Workflows
Clinical Impact
The global diagnostics market is transforming. New Zealand healthcare needs a specialist bridge.
Rapid advances across antimicrobial resistance, sepsis diagnostics, point-of-care testing, digital pathology AI, and precision medicine are reshaping clinical decision-making worldwide. The challenge for New Zealand and Oceania is access — adopting these technologies in a way that is practical, evidence-grounded, and aligned with local clinical requirements.
Translyx connects global diagnostic innovation with local clinical adoption. We represent authorised partner solutions such as Aiforia digital pathology AI, position Privexa-built protected software for healthcare, and introduce diagnostic technologies — with the clinical rigour and governance that successful adoption requires.
Focus areas
Diagnostic Technology
AMR, sepsis, POCT, endocrinology, cardiac markers, oncology biomarkers, and precision medicine.
Digital Pathology AI
Authorised Aiforia partner for clinical, preclinical, and research pathology in New Zealand.
Governed Clinical AI
Reviewer-gated evidence workflows, field-level data protection, and privacy-first software.
Regional Reach
New Zealand national, expanding into Australia and Pacific Island markets.
One company. A governed bridge between global innovation and local clinical adoption.
Translyx connects authorised digital pathology AI, Privexa-built protected software, and a clinical diagnostic pipeline — under one accountable, New Zealand-based partner.
Clinical technology partner
Translyx Limited
Auckland, New Zealand · Oceania
Aiforia is an authorised partner solution represented by Translyx in New Zealand — not a Translyx-owned product. Privexa-built products are developed by Privexa Limited and clinically positioned through Translyx.
Authorised partner solutions and Privexa-built protected AI, clinically positioned through Translyx.
One portfolio spanning digital pathology AI, protected software, and reviewer-gated evidence workflows.
Authorised partner solution
Aiforia Digital Pathology AI
AI-assisted digital pathology workflows for clinical, preclinical, and research applications — including Aiforia Clinical Suites and Aiforia Create Platform.
Explore AiforiaBuilt by Privexa
Privexa AI Wrapper
A secure LLM gateway that intercepts and replaces sensitive data with safe tokens before any message reaches an AI system. Responses are restored with original context automatically.
Explore AI WrapperPlatformBuilt by Privexa
Privexa Cloud Shield
Field-level tokenisation for cloud data pipelines. Sensitive fields are replaced before reaching cloud platforms — the local mapping vault is reversible only inside your perimeter.
Explore Cloud ShieldPlatformBuilt by Privexa
Privexa Scribe
Clinical consultation recording with full PHI protection. Record, transcribe, and generate clinician-ready notes — sensitive data never leaves your boundary.
Explore ScribePlatformBuilt by Privexa
Privexa Trace
Reviewer-gated synthetic control arm workflows with manual benchmark comparison, lineage, visible limitations, and submission-oriented packaging.
Explore TracePlatformBuilt by Privexa
ClinicalTriage
Audited clinical pathway and referral grading support with role-based access, specialist review, and full audit trail. Designed for authorised clinical users.
Explore ClinicalTriagePlatformGoverned AI workflows — not AI with governance bolted on.
Governance, traceability, visible limitations, and reviewer gates are structural features of the workflow — present by design, not added as disclaimers after the fact.
Reviewer gate
A mandatory human sign-off step before AI-assisted output is generated. Governance stays inside the workflow — never bolted on after.
Full lineage
Every dataset choice, decision, and workflow stage remains traceable end-to-end, ready for review and submission.
Field-level protection
Sensitive clinical data is shielded field by field, so identifiable information never reaches a model in its original form.
Visible limitations
Boundaries and assumptions are declared and transparent — honest about what the system does and does not do.
Privexa software
Privexa builds the protected software layer. Translyx delivers the clinical adoption.
Translyx works with Privexa Limited to bring protected AI software into healthcare, diagnostics, research, and evidence workflows. Privexa builds the software layer. Translyx focuses on clinical positioning, diagnostic adoption, local partnerships, and healthcare implementation.
AI Wrapper
Secure LLM gateway for privacy-preserving AI use
Cloud Shield
Field-level protection for cloud platforms and data workflows
Scribe
Privacy-protected clinical documentation and structured notes
Trace
Reviewer-gated evidence and synthetic control workflows
Built for the organisations shaping clinical care in Oceania
Hospitals & Laboratories
Adoption support for diagnostic and digital pathology technologies across acute and lab settings.
Pathology Groups
AI-assisted digital pathology workflows for clinical, preclinical, and research reporting.
Research Teams
Governed evidence workflows, image analysis, and reviewer-gated synthetic control arms.
Pharma & CROs
Protected AI workflows and submission-oriented evidence packaging for clinical programmes.
Health Innovation Teams
A local bridge to evaluate, govern, and deploy clinical AI with privacy and confidence.
Talk to Translyx about your clinical technology priorities.
Whether the focus is diagnostic product evaluation, digital pathology AI, AI data protection, or reviewer-gated evidence workflows — the Translyx team can help identify the right fit for your organisation.